横紋筋肉腫(Rhabdomyosarcoma):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Rhabdomyosarcoma - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5859IDB
◆発行日:2014年12月24日
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:72
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥222,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[横紋筋肉腫(Rhabdomyosarcoma):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら
当調査レポートでは、世界における横紋筋肉腫(Rhabdomyosarcoma)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・横紋筋肉腫(Rhabdomyosarcoma)の概要
・横紋筋肉腫(Rhabdomyosarcoma)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・横紋筋肉腫(Rhabdomyosarcoma)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・横紋筋肉腫(Rhabdomyosarcoma)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・横紋筋肉腫(Rhabdomyosarcoma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
*** レポート概要(サマリー)***

Rhabdomyosarcoma – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Rhabdomyosarcoma – Pipeline Review, H2 2014’, provides an overview of the Rhabdomyosarcoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhabdomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Rhabdomyosarcoma – Overview 7
Pipeline Products for Rhabdomyosarcoma – Comparative Analysis 8
Rhabdomyosarcoma – Therapeutics under Development by Companies 9
Rhabdomyosarcoma – Therapeutics under Investigation by Universities/Institutes 10
Rhabdomyosarcoma – Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Rhabdomyosarcoma – Products under Development by Companies 13
Rhabdomyosarcoma – Products under Investigation by Universities/Institutes 14
Rhabdomyosarcoma – Companies Involved in Therapeutics Development 15
Arisaph Pharmaceuticals, Inc. 15
Bellicum Pharmaceuticals, Inc. 16
Celgene Corporation 17
Eisai Co., Ltd. 18
GlaxoSmithKline plc 19
Neotropix, Inc. 20
Novartis AG 21
Rhabdomyosarcoma – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ARI-4175 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy for GD2 Expressing Solid Tumors – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
celyvir – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, and NY-ESO-1 for Oncology – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
E-7438 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
everolimus – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NTX-010 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
paclitaxel albumin bound – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pazopanib hydrochloride – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Rhabdomyosarcoma – Recent Pipeline Updates 56
Rhabdomyosarcoma – Dormant Projects 69
Rhabdomyosarcoma – Discontinued Products 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

[List of Tables]
Number of Products under Development for Rhabdomyosarcoma, H2 2014 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 15
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 16
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2014 17
Rhabdomyosarcoma - Pipeline by Eisai Co., Ltd., H2 2014 18
Rhabdomyosarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 19
Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H2 2014 20
Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 56
Rhabdomyosarcoma - Dormant Projects, H2 2014 69
Rhabdomyosarcoma - Discontinued Products, H2 2014 70

[List of Figures]
Number of Products under Development for Rhabdomyosarcoma, H2 2014 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Top 10 Targets, H2 2014 23
Number of Products by Stage and Top 10 Targets, H2 2014 24
Number of Products by Top 10 Mechanism of Actions, H2 2014 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 27
Number of Products by Top 10 Routes of Administration, H2 2014 28
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 29
Number of Products by Top 10 Molecule Types, H2 2014 30
Number of Products by Stage and Top 10 Molecule Types, H2 2014 31

*** 掲載企業 ***

Arisaph Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.
Celgene Corporation
Eisai Co., Ltd.
GlaxoSmithKline plc
Neotropix, Inc.
Novartis AG

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5859IDB )"横紋筋肉腫(Rhabdomyosarcoma):治療薬開発パイプライン動向(2014年下半期版)" (英文:Rhabdomyosarcoma - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。